AR110183A1 - IMPROVED COMPOSITION OF LANSOPRAZOL AND SIMETICONE AND PROCESS TO PREPARE IT - Google Patents

IMPROVED COMPOSITION OF LANSOPRAZOL AND SIMETICONE AND PROCESS TO PREPARE IT

Info

Publication number
AR110183A1
AR110183A1 ARP170103219A ARP170103219A AR110183A1 AR 110183 A1 AR110183 A1 AR 110183A1 AR P170103219 A ARP170103219 A AR P170103219A AR P170103219 A ARP170103219 A AR P170103219A AR 110183 A1 AR110183 A1 AR 110183A1
Authority
AR
Argentina
Prior art keywords
simethicone
microgranules
lansoprazol
simeticone
prepare
Prior art date
Application number
ARP170103219A
Other languages
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of AR110183A1 publication Critical patent/AR110183A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Reivindicación 1: Una composición farmacéutica de administración oral que comprende entre 120 mg y 200 mg de Simeticona y entre 15 mg y 60 mg de Lansoprazol o Dexlansoprazol, caracterizada porque la Simeticona se encuentra bajo la forma de microgránulos de elevada concentración, siendo dicha concentración mayor o igual a 500 mg/g, en donde los microgránulos están formados por esferas de azúcar, dióxido de silicio coloidal, carbonato de magnesio y opcionalmente otros excipientes farmacéuticos. Reivindicación 6: Un proceso para preparar microgránulos con una concentración mayor o igual a 500 mg/g de Simeticona caracterizado porque consiste en colocar, en una paila de recubrimiento de pared sólida o en un equipo de lecho fluido tipo rotor tangencial, esferas de azúcar y mientras se encuentran en rodamiento humectarlas a intervalos regulares con Simeticona y secarlas con una mezcla definida de Dióxido de Silicio Coloidal y Carbonato de Magnesio.Claim 1: A pharmaceutical composition for oral administration comprising between 120 mg and 200 mg of Simethicone and between 15 mg and 60 mg of Lansoprazole or Dexlansoprazole, characterized in that Simethicone is in the form of high concentration microgranules, said concentration being higher or equal to 500 mg / g, wherein the microgranules are formed by sugar spheres, colloidal silicon dioxide, magnesium carbonate and optionally other pharmaceutical excipients. Claim 6: A process for preparing microgranules with a concentration greater than or equal to 500 mg / g of Simethicone characterized in that it consists in placing, in a solid-wall coating pan or in a tangential rotor fluid bed equipment, sugar spheres and while they are in the bearing, wet them at regular intervals with Simethicone and dry them with a defined mixture of Colloidal Silicon Dioxide and Magnesium Carbonate.

ARP170103219A 2016-12-14 2017-11-17 IMPROVED COMPOSITION OF LANSOPRAZOL AND SIMETICONE AND PROCESS TO PREPARE IT AR110183A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016016587A MX2016016587A (en) 2016-12-14 2016-12-14 Improved composition of lansoprazole and simeticone and method for preparing same.

Publications (1)

Publication Number Publication Date
AR110183A1 true AR110183A1 (en) 2019-03-06

Family

ID=62558163

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103219A AR110183A1 (en) 2016-12-14 2017-11-17 IMPROVED COMPOSITION OF LANSOPRAZOL AND SIMETICONE AND PROCESS TO PREPARE IT

Country Status (9)

Country Link
AR (1) AR110183A1 (en)
BR (1) BR112019011966A2 (en)
CL (1) CL2019001462A1 (en)
CO (1) CO2019006693A2 (en)
CR (1) CR20190290A (en)
DO (1) DOP2019000145A (en)
MX (1) MX2016016587A (en)
PE (1) PE20191654A1 (en)
WO (1) WO2018109693A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
RU2602745C2 (en) * 2011-12-14 2016-11-20 Дисфар Интернэшнл Б.В. Composition with simeticon

Also Published As

Publication number Publication date
CO2019006693A2 (en) 2019-07-10
DOP2019000145A (en) 2019-08-15
CL2019001462A1 (en) 2019-08-23
WO2018109693A1 (en) 2018-06-21
BR112019011966A2 (en) 2019-11-05
MX2016016587A (en) 2018-06-13
PE20191654A1 (en) 2019-11-07
CR20190290A (en) 2019-11-18

Similar Documents

Publication Publication Date Title
MA38399A1 (en) Formulation in tablet form, useful for treating acute heart failure and chronic heart failure
PE20211069A1 (en) COMPOSITION INCLUDING 5'-METHYLSEELENOADENOSINE, SELENOADENOSYL-L-HOMOCYSTEIN AND GLUTAMYL-METHYLSELENOCYSTEINE RANGE
CL2018001686A1 (en) Methods and compositions particularly for the treatment of attention deficit disorder (divisional application 201701026)
WO2014175917A8 (en) Multiparticulate l-menthol formulations and related methods
AR096045A1 (en) PHARMACEUTICAL COMPOSITION AND FORMULATION TO PREVENT OR TREAT DRY EYE SYNDROME
EP4295853A3 (en) Formulations of brincidofovir
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
SG11201912172YA (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
AR110183A1 (en) IMPROVED COMPOSITION OF LANSOPRAZOL AND SIMETICONE AND PROCESS TO PREPARE IT
MX2015015537A (en) Nicotine lozenge formulation.
AR094658A1 (en) FORMULATION OF LIPOSOMAL REHYDRATION SALTS
EP3730130C0 (en) Oral administration formulation of blueberry extract as a coadjuvant for preserving the health of human precorneal film
DOP2019000190A (en) QUICK RELEASE COMPOSITION OF CINITAPRIDA AND SYMETICONE AND PROCESS TO PREPARE IT.
TH183323B (en) Oral formulations of defiraxirox (DEFERASIROX)
Wang Small intestinal ulcers and gastrointestinal bleeding leading to megaloblastic anaemia: case report
CN302051838S (en) wet wipes box
UA100701U (en) MEANS IN THE FILM FORM FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE ORAL MUSCLE
CN302289605S (en) Socket (medium power in-line socket)
CN302496726S (en) electrical connector
CN302467610S (en) electrical connector
CN302289606S (en) Plug (medium power straight plug)
UA112089C2 (en) SOLID MEDICINAL FORM OF SODIUM AND SOPHODIC EFFECTS OF DOXYLAMINE COMBINED
CN302536147S (en) Cartoon Toys (633-1)
CN302517191S (en) Harmful Substance Extractor
UA93426U (en) GEL VIEW COMPOSITION FOR THE TREATMENT OF ACNE DISEASE